Please assess the completion status of the following clinical trial:

Trial Title: A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Signed an informed consent form (ICF)~* Medically stable in the investigator's clinical judgment on the basis of physical examination, medical history, and vital signs performed at screening~* Before randomization, a woman must be either: a. Not of childbearing potential; b. Of childbearing potential and practicing an acceptable effective method of birth control and agrees to remain on such a method of birth control from signing the informed consent form (ICF) until at least 3 months post Dose 1 vaccination or 28 days post Dose 2 vaccination or 3 months post booster vaccination (Groups 5-6 only), whichever comes later. Use of hormonal contraception should start at least 28 days before the first administration of study vaccine. Acceptable effective methods for this study include: 1) hormonal contraception; 2) intrauterine device (IUD); 3) intrauterine hormone-releasing system (IUS); 4) male or female condom with or without spermicide; 5) cap, diaphragm, or sponge with a vaginal spermicide; 6) vasectomized partner (the vasectomized partner should be the sole partner for that participant); 7) sexual abstinence~* Women of childbearing potential must have a negative urine Beta-human chorionic gonadotropin (Beta-hCG) pregnancy test at screening and immediately prior to each study vaccine administration~* Available and willing to participate for the duration of the study and follow-up visit~* Willing to provide verifiable identification~Exclusion Criteria:~* Having received any candidate Ebola vaccine~* Diagnosed with Ebola virus disease (EVD), or prior exposure to Ebola virus, including travel to an area with Ebola outbreak less than 1 month prior to screening (if applicable)~* Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines), including known allergy to egg, egg products, and aminoglycosides~* Presence of acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (\>=) 38.0ºCelcius on Day 1. Participants with such symptoms will be excluded from enrollment at that time but may be rescheduled for enrollment at a later date~* Human immunodeficiency virus (HIV) type 1 or type 2 infection, based on the medical history reported by the participant~* Pregnant, breast-feeding~* History of an underlying clinically significant acute or chronic medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Active Vaccine: Group 1 (Ad26.ZEBOV-Lot A, MVA-BN-Filo-Lot 1) (Type: EXPERIMENTAL): Participants will receive Intramuscular injection (0.5 milliliter \[mL\]) of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5\*10\^10 viral particle(s) \[vp\], Lot A) on Day 1, followed by Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1\*10\^8 infectious unit(s) \[Inf U\], Lot 1) on Day 57.
- Active Vaccine: Group 2 (Ad26.ZEBOV-Lot B, MVA-BN-Filo-Lot 2) (Type: EXPERIMENTAL): Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot B) on Day 1, followed by MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 2) on Day 57.
- Active Vaccine: Group 3 (Ad26.ZEBOV-Lot C, MVA-BN-Filo-Lot 3) (Type: EXPERIMENTAL): Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot C) on Day 1, followed by MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 3) on Day 57.
- Control Vaccine: Group 4 (Placebo) (Type: PLACEBO_COMPARATOR): Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9 percent \[%\] saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57.
- Booster Cohort: Group 5 (Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV) (Type: EXPERIMENTAL): Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, a single Lot) on Day 1, followed by MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, a single Lot) on Day 57 and a booster dose of Ad26.ZEBOV (at a dose of 5\*10\^10 vp, a single Lot) 4 months after Dose 2 (on Day 177).
- Booster Cohort: Group 6 (Placebo) (Type: PLACEBO_COMPARATOR): Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9% saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57 and a booster dose of matching placebo on Day 177.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete